Ethical and legal issues in treatment of schizophrenic patients with neuroleptics in childhood and youth;Ethische und rechtliche probleme bei behandlungen schizophrener patienten mit neuroleptika im kindes- und jugendalter

Nervenheilkunde

Volumn 22, Issue 2, 2003, Pages 75-79

  Fegert, Jörg M ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Evidence based medicine; Individual case trial; Off label use; Psycho pharma therapy; Schizophrenic psychotic conditions during childhood and youth

Indexed keywords

NEUROLEPTIC AGENT;

CHILD; CHILD HEALTH CARE; DRUG INDICATION; DRUG LEGISLATION; DRUG RESEARCH; ETHICS; EUROPE; GERMANY; HEALTH CARE QUALITY; HUMAN; INFORMED CONSENT; JUSTICE; LEGAL ASPECT; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA;

EID: 0037251079     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1624379     Document Type: Review

References (18)

1. Armenteros JL, Whitaker AH, Welikson M, et al. Risperidone in adolescents with schizophrenia: an open pilot study. J Am Acad Child Adolesc Psychiatry 1997; 36 (5): 694-700.
2. Buckley PF. Broad Therapeutic Use of Atypical Antipsychotic Medications. Biol Psychiatry 2001; 50: 912-24.
3. Campbell M, Rapoport JL, Simpson GM. Antipsychotics in Children and Adolescents. J Am Acad Child Adolesc Psychiatry 1999; 38: 537-45.
4. Findling RL, Fegert JM, de Smedt G. Interim Results from a Multicenter Study of the Long-Term Safety and Efficacy of Risperidone in Children and Adolescents with Severe Disruptive Behaviors and Subaverage IQ. Orlando/ Florida: APA Institute on Psychiatric Services 2001. (October 10-14).
5. Gillberg C. Typical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatry 2002; 9: I/2-I/8.
6. Grcevich SJ, Findling RL, Rowane WA, et al. Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. J Child Adolesc Psychopharmacol 1996; 6 (4): 251-7.
7. Jobson KO, Potter WZ. International Psychopharmacology Algorithm Project Report. Introduction. Psychopharmacol Bull 1995; 31: 457-507.
8. Krisgnamoorthy J, King BH. Open-label Olanzapine Treatment in Five Preadolescent Children. J Chil Adolesc Psychopharmacology 1998; 8: 107-13.
9. Kumra S, Jacobsen LK, Lenane M, et al. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry 1998; 37 (4): 377-85.
10. Madoki M. Olanzapine in The Treatment of Early Onset Schizophrenia in Children and Adolescents. Biol Psychiatry 1997; 41: 15.
11. McConville BJ, Arvanitis LA, Thyrum PT, et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 2000; 61 (4): 252-60.
12. Quintana H, Keshavan M. Case Study: Risperidone in Children and Adolescents with Schizophrenia. J Am Acad Child Adolesc Psychiatry 1995; 34: 1292-6.
13. Rothärmel S, Wolfslast G, Fegert JM. Informed Conset, ein kinderfeindliches Konzept? MedR 1999; 7: 293-8.
14. Rothärmel S, Fegert JM. Zur rechtlichen Verbindlichkeit von Leitlinien. Zeitschrift für Kinder und Jugendpsychiatrie und Psychotherapie 2000; 28 (4): 275-84.
15. Shaw JA, Lewis JE, Pascal S, et al. A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 2001; 11 (4): 415-24.
16. Toren P, Laor N, Weizman A. Use of atypical neuroleptics in child and adolescent psychiatry. J Clin Psychiatry 1998; 59 (12): 644-56.
17. Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of Prolactin Levels by Atypical Antipsychotics. Am J Psychiatry 2002; 159: 133-5.
18. Vitiello B, Jensen PS, Hoagwood K. Integrating Science and Ethics in Child and Adolescent Psychiatry Research. Biol Psychiatry 1999; 46: 1044-9.